Back to Journals » Clinical Ophthalmology » Volume 6

Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs

Authors Inoue K, Setogawa, Higa, Moriyama, Wakakura M, Tomita

Received 10 December 2011

Accepted for publication 11 January 2012

Published 10 February 2012 Volume 2012:6 Pages 231—235

DOI https://doi.org/10.2147/OPTH.S29062

Review by Single-blind

Peer reviewer comments 2


Kenji Inoue1, Akira Setogawa1, Risako Higa1, Ryo Moriyama1, Masato Wakakura1, Goji Tomita2
1Inouye Eye Hospital, Chiyoda-ku, Tokyo, Japan; 22nd Department of Ophthalmology, Toho University School of Medicine, Tokyo, Japan

Introduction: Travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops are available in Japan. We prospectively investigated the intraocular pressure (IOP)-decreasing effect of travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops and the adherence of patients to the administration protocol.
Materials and methods: We studied 43 eyes from 43 patients diagnosed with primary open-angle glaucoma, who were using prostaglandin analogs and ß-blockers. The prostaglandin analogs and ß-blockers were discontinued, and the treatment regimen was changed to travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops without any washout period. IOP before and at 1 month, 3 months, and 6 months after the treatment change was evaluated and compared. A questionnaire about protocol adherence was administered 1 month after the treatment change.
Results: IOP was 15.7 ± 2.9 mmHg before the change, 15.5 ± 2.7 mmHg at 1 month after the change, 15.3 ± 3.6 mmHg at 3 months after the change, and 15.8 ± 3.2 mmHg at 6 months after the change, and none of the differences were significant (P = 0.191). The responses to the questionnaire showed that cases where eye drop administration was forgotten decreased after the treatment change. Moreover, because of changes in eye drops, 19.0% of patients had irritation. More than half (54.8%) of the patients preferred travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops. Seven patients (16.3%) discontinued eye drop use because of adverse reactions within 6 months after the change.
Conclusion: When the treatment regimen was changed from prostaglandin analogs and ß-blockers to travoprost 0.004%/timolol maleate 0.5% fixed combination eye drops, administration protocol adherence increased and IOP was preserved; however, adverse reactions appeared in about 16% of the cases.

Keywords: travoprost 0.004%/timolol maleate 0.5% fixed combination, ß-blockers, prostaglandin analog, change, intraocular pressure

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]